NCT07327489 Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
| NCT ID | NCT07327489 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Elephas |
| Condition | Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,000 participants |
| Start Date | 2025-04-14 |
| Primary Completion | 2035-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,000 participants in total. It began in 2025-04-14 with a primary completion date of 2035-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study will collect tumor specimens with correlated clinical and demographic data from patients who are undergoing a biopsy or similar procedure to obtain tumor tissue as a normal course of their medical management or diagnostic work-up for suspected or confirmed cancer.
Eligibility Criteria
Inclusion Criteria: 1. Able and willing to provide informed consent for participation 2. Age ≥18 years at time of consent. 3. Have a suspected or confirmed cancer diagnosis that is to be evaluated by means of a biopsy. 4. Subjects who are newly diagnosed or have suspected cancer must be treatment-naïve at the time of biopsy. All other subjects should have the biopsy performed before starting their next line of treatment. Exclusion Criteria: 1. Have a known auto-immune disease or prior condition (prior organ transplant, chronic kidney or liver disease) that renders them ineligible for immunotherapy (IO) treatment. 2. Severely immunocompromised person(s). Examples include patients on immunosuppressants, HIV positive patients on antiretrovirals, post transplantation patients. 3. Pregnant person(s).
Frequently Asked Questions
Who can join the NCT07327489 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07327489 currently recruiting?
Yes, NCT07327489 is actively recruiting participants. Visit ClinicalTrials.gov or contact Elephas to inquire about joining.
Where is the NCT07327489 trial being conducted?
This trial is being conducted at Fort Smith, United States, Frederick, United States, Springfield, United States, St Louis, United States and 4 additional locations.
Who is sponsoring the NCT07327489 clinical trial?
NCT07327489 is sponsored by Elephas. The trial plans to enroll 2,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.